RecruitingPhase 2NCT06050252
Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery
Studying Cholangiocarcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Hop S Tran CaoUniversity of Texas MD Anderson Cancer Center LAO
- Intervention
- Biopsy Procedure(procedure)
- Enrollment
- 27 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2027
Study locations (30)
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
- Los Angeles General Medical Center, Los Angeles, California, United States
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
- UCHealth University of Colorado Hospital, Aurora, Colorado, United States
- Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut, United States
- Smilow Cancer Hospital Care Center-Fairfield, Fairfield, Connecticut, United States
- Smilow Cancer Hospital Care Center at Glastonbury, Glastonbury, Connecticut, United States
- Smilow Cancer Hospital Care Center at Greenwich, Greenwich, Connecticut, United States
- Smilow Cancer Hospital Care Center - Guilford, Guilford, Connecticut, United States
- Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States
- Yale University, New Haven, Connecticut, United States
- Yale-New Haven Hospital North Haven Medical Center, North Haven, Connecticut, United States
- Smilow Cancer Hospital Care Center at Long Ridge, Stamford, Connecticut, United States
- Smilow Cancer Hospital-Torrington Care Center, Torrington, Connecticut, United States
- Smilow Cancer Hospital Care Center-Trumbull, Trumbull, Connecticut, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06050252 on ClinicalTrials.govOther trials for Cholangiocarcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07478523FAPI-PET Value for the Initial Screening of Pancreatic and Biliary CancersUniversity Hospital, Bordeaux
- RECRUITINGNANCT07476651Scout Dose of Resin MicrospheresSeoul National University Hospital
- RECRUITINGPHASE2NCT06728410A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or RearrangementMehmet Akce
- RECRUITINGPHASE2NCT07201519Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion ChemotherapyMichael J Cavnar, MD
- RECRUITINGPHASE2NCT07223307REGULUS: MRI-guided Adaptive SABR for Liver CancersStanford University
- RECRUITINGPHASE2NCT07260175Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 CholangiocarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- RECRUITINGNANCT06735560Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NENNantes University Hospital
- RECRUITINGNANCT07263217Mechanistic Study on the Protective and Regenerative Effects of Spirulina in Hepatectomy-Related Liver InjurySecond Affiliated Hospital, School of Medicine, Zhejiang University